Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAC Tissue Burden in HIV
NCT00001039Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clarithromycin and ethambutol in Mycobacterium avium complex infection (MAC), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Feasibility of using culture and staining techniques to quantify tissue MAC burden in bone marrow at 8 weeks. Status: completed.
02
Drugs
clarithromycinethambutol
03
Conditions
Mycobacterium avium complex infection (MAC)
Beyond the preview
Go deeper on NCT00001039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001039.